Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo New Product Program, Quality Control Back On Track In FY 2002

This article was originally published in The Tan Sheet

Executive Summary

Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.

You may also be interested in...



Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter

Perrigo's vitamin and supplement sales posted double-digit gains in the fiscal first quarter ended Sept. 29, fueled primarily by letter vitamins and glucosamine/ chondroitin supplements, the firm announced Oct. 23.

Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter

Perrigo's vitamin and supplement sales posted double-digit gains in the fiscal first quarter ended Sept. 29, fueled primarily by letter vitamins and glucosamine/ chondroitin supplements, the firm announced Oct. 23.

Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter

Perrigo's vitamin and supplement sales posted double-digit gains in the fiscal first quarter ended Sept. 29, fueled primarily by letter vitamins and glucosamine/ chondroitin supplements, the firm announced Oct. 23.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS091830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel